Drug Trial Radar · NCT00271401
A Study Comparing the Efficacy and Safety of Intracoronary Stenting With or Without Abciximab, an Anti-Platelet Therapy, and Conventional Coronary Angioplasty With Abciximab
Last checked: Nov 20, 2026Latest source record: May 25, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,399
Actual
Start
Jul 1996
Primary completion
Sep 1997
Study completion Sep 1997
Sponsor
- Lead sponsor
- Centocor, Inc.Johnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Jan 2, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the effectiveness and safety of intracoronary stenting with or without abciximab, an anti-platelet therapy, and conventional coronary angioplasty with abciximab in patients undergoing percutaneous coronary intervention.
Conditions
- Angioplasty, Transluminal, Percutaneous Coronary
Interventions
AngioplastyOther
Intracoronary StentOther
AbxicimabDrug
HeparinDrug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With any one of these: Deaths, Myocardial Infarctions, or Urgent Repeat RevascularizationsTime frame: Up to 30 days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.